0001209191-22-063059.txt : 20221230
0001209191-22-063059.hdr.sgml : 20221230
20221230211230
ACCESSION NUMBER: 0001209191-22-063059
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20221221
FILED AS OF DATE: 20221230
DATE AS OF CHANGE: 20221230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Castelli Jeff
CENTRAL INDEX KEY: 0001569225
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 221503088
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 921-7600
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-12-21
0
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001569225
Castelli Jeff
3675 MARKET STREET
PHILADELPHIA
PA
19104
0
1
0
0
Chief Development Officer
Common Stock
304255
D
Stock Options (right to buy)
12.28
2025-06-01
Common Stock
50000
D
Stock Options (right to buy)
9.03
2026-01-04
Common Stock
50000
D
Stock Options (right to buy)
15.67
2028-01-03
Common Stock
39762
D
Stock Options (right to buy)
10.04
2029-01-02
Common Stock
82644
D
Stock Options (right to buy)
9.55
2030-01-02
Common Stock
107575
D
Stock Options (right to buy)
21.78
2031-01-04
Common Stock
46396
D
Stock Options (right to buy)
12.11
2032-01-03
Common Stock
108266
D
Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock.
All of the options in this row are fully vested and exercisable as of December 21, 2022.
The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested.
The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested.
The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested.
The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.
/s/ Christian Formica, Attorney-in-Fact
2022-12-30
EX-24
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
The undersigned hereby constitutes and appoints each of Ellen Rosenberg,
Daphne Quimi and Christian Formica, or any of them signing singly, and with full
power of substitution, the undersigned's true and lawful attorney-in-fact to:
1. prepare and execute in the undersigned's name and on the
undersigned's behalf, and submit to the U.S. Securities and Exchange Commission
(the "SEC") a Form ID, including amendments thereto, and any other documents
necessary or appropriate to obtain codes and passwords enabling the undersigned
to make electronic filings with the SEC of reports required by Section16(a) of
the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Amicus Therapeutics, Inc., a Delaware
corporation (the "Company"), Forms 3, 4, and5 in accordance with Section 16(a)
of the Securities Exchange Act of 1934 and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4,
or 5, complete and execute any amendment or amendments thereto, and file any
such Form or amendment with the SEC and any stock exchange or similar authority,
including filing this power of attorney with the SEC; and
4. take any other action necessary in connection with the foregoing
which, in the opinion of such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this power of attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act requisite, necessary, or proper to
be done in the exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue of this power of
attorney and the rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such capacity at the request
of the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.
This power of attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of December, 2022.
/s/ Jeffrey P. Castelli
Signature
Jeffrey P. Castelli
Print Name